423 results about "Spike Protein" patented technology

The invention discloses a fatty acid modified coronavirus antigen and application thereof, and belongs to the field of biological medicine. The fatty acid modified coronavirus antigen contains fatty acid modified N-terminal cysteine (Cys) and a coronavirus antigen, and can contain a connecting structural domain; the coronavirus antigen is a coronavirus spike protein (S protein) receptor binding domain (RBD). The fatty acid modified coronavirus S protein RBD can be self-polymerized into nanoparticles, and compared with the RBD which is not subjected to fatty acid modification, the antigen can induce faster and higher humoral immunity through injection immunity, can induce mucosal immunity and humoral immunity through respiratory tract atomization immunity, and is a candidate mucosal vaccine with potential medical value.

The invention discloses a specific antibody capable of combining with a coronavirus SARS-CoV-2 and an SARS-CoV spike protein (SARS-CoV spike protein), and an application of the specific antibody capable of combining with the coronavirus SARS-CoV-2 and the SARS-CoV spike protein. The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention comprises CDRs with a specific sequence, can be specifically combined with SARS-CoV-2 and SARS-CoV spike protein, and has a relatively strong binding reaction with spike protein of another highly pathogenic coronavirus MERS-CoV at the same time. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an SARS-CoV and SARS-CoV-2 infection detection method.

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

The invention discloses a porcine epidemic diarrhea virus antigen fusion protein, a coding gene and a porcine epidemic diarrhea vaccine prepared from the porcine epidemic diarrhea virus antigen fusion protein. The method comprises the following steps: screening to obtain a homosensory sequence of the spike protein of the porcine epidemic diarrhea virus, and fusing the homosensory sequence with a monomeric porcine ferritin heavy chain subunit to obtain an antigen fusion protein; in order to improve the expression quantity or the titer of the antigen fusion protein, the obtained antigen fusion protein is subjected to sequence optimization and then subjected to single-site or multi-site mutation, and the expression quantity and the titer of the obtained mutant are remarkably improved. According to the invention, a recombinant protein is expressed by using a silkworm or AcMNPV-insect cell and other eukaryotic expression systems to obtain a self-assembled ferritin nanoparticle antigen for displaying an S protein antigen protein on the surface of a cage structure of porcine ferritin, and a vaccine prepared from the prepared nanoparticle antigen can induce a widely neutralized anti-porcine epidemic diarrhea virus antibody; the porcine epidemic diarrhea virus vaccine has the potential of becoming a universal porcine epidemic diarrhea virus vaccine with cross immune efficacy.

The invention discloses a specific antibody MR-34 for targeting a coronavirus MERS-CoV spike protein RBD (Radial Basis Disease). The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention contains CDRs with a specific sequence, and can be specifically combined with an MERS-CoV spike protein RBD structural domain. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an MERS-CoV infection detection method.

Lipid nanoparticles (LNPs) encapsulating self-amplifying mRNA, compositions, and methods of use of the novel nucleic acid constructs and compositions are disclosed. The LNP constructs comprise a novel ionizable lipid. The novel sa-mRNA constructs encode a modified SARS-CoV-2 spike protein in which the polynucleotide has been truncated to comprise no nucleotides encoding SARS-CoV-2 transmembrane domain and short cytoplasmic domain amino acids, as well as immunomodulators. The sa-mRNA may be used as a therapeutic, diagnostic and / or prophylactic agent for mammalian cells or organs.

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

The invention discloses a system for evaluating an ADE effect and application thereof. The system comprises: (i) and (iii); (ii) and (iii); or (i), (ii) and (iii); (i) is a Middle East Respiratory Syndrome Coronavirus pseudovirus, (ii) is an antibody that targets the receptor binding domain of the Middle East Respiratory Syndrome Coronavirus, and (iii) is a cell that overexpresses CD32B; the cells are CHO cells; the pseudovirus contains a Spike protein coding gene of the Middle East Respiratory Syndrome Coronavirus. According to the invention, the ADE activity of the Middle East respiratory coronavirus antibody is identified in vitro by using MERS-CoV pseudovirus and cells for exogenous expression of CD32B. Compared with an immune cell Raji and an ADE evaluation system based on exogenous expression CD32A cells, the system provided by the invention is more sensitive, and is a potential system for evaluating the ADE effect of the Middle East respiratory coronavirus.

The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.

The present disclosure relates to antibodies useful in the prevention, treatment and / or diagnosis of coronavirus infections, as well as diseases and / or complications associated with coronavirus infections, including COVID-19. In particular, the present disclosure relates to antibodies capable of binding to the spike protein of the coronavirus SARS-CoV-2 and uses thereof.

The disclosure relates to antibodies useful for the prevention, treatment and / or diagnosis of coronavirus infections, and diseases and / or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

The invention relates to the technical field of medical care informatics, in particular to a respiratory infectious disease risk early warning method and system. The method comprises the following steps: acquiring a respiratory tract sample of a mutant virus infected person; the method comprises the following steps: extracting a mutant virus from a respiratory tract sample, carrying out genome sequencing on the mutant virus, positioning starting and ending positions of a spike protein coding gene in a genome by virtue of a biological information comparison method, extracting a spike protein coding sequence, and translating the spike protein coding sequence into an amino acid sequence; inputting the amino acid sequence into an immune escape prediction model to predict the immune escape score of the mutant virus; and performing risk assessment based on the immune escape score in combination with clinical monitoring information, and outputting a respiratory infectious disease risk early warning value. According to the invention, the risk of respiratory infectious diseases can be early warned better.

The present disclosure provides isolated immunogenic polypeptides comprising variant coronavirus spike proteins that are variants of a native coronavirus spike protein or fragment thereof. The present disclosure also provides compositions comprising the isolated immunogenic polypeptides and methods of making and using such compositions.

The invention discloses a VZV antigen variant, nucleic acid, a pharmaceutical composition and application of the VZV antigen variant. The VZV antigen variant has a Y582G difference compared with an amino acid sequence as shown in SEQ ID NO: 1; and / or the VZV antigen variant has the deletion of 561 to 623 sites, 569 to 623 sites or 574 to 623 sites compared with the amino acid sequence as shown in SEQ ID NO: 1, and / or the VZV antigen variant has the deletion of 561 to 623 sites, 569 to 623 sites or 574 to 623 sites; and / or the VZV antigen variant is a modification having a protein transmembrane region and an intracellular region compared with the amino acid sequence as shown in SEQ ID NO: 1, and the modification of the protein transmembrane region and the intracellular region is that the transmembrane region and the intracellular region of the original VZV antigen are replaced by a transmembrane region of SARS-CoV-2Spike protein or a transmembrane region of influenza H protein. Compared with the VZV antigen in the prior art, the VZV antigen variant has stronger immunogenicity, can obtain higher binding antibody titer, and has higher protective efficacy.

The invention discloses a cell membrane protein replacement type oncolytic virus vector and application thereof. The cell membrane protein replacement type oncolytic virus vector is rhabdoviridae virus, and a nucleotide sequence for coding G protein in a genome of the rhabdoviridae virus is replaced by a nucleotide sequence for coding an antibody and a nucleotide sequence for coding a spike protein truncation of coronavirus. The invention also discloses a construction method of the cell membrane protein replacement type oncolytic virus vector for expressing the antibody, the non-replicated virus vector is used for expressing the antibody sequence for the first time, and meanwhile, the novel coronavirus cell membrane protein is embedded into the virus surface, so that the cell membrane protein replacement type oncolytic virus vector can be rapidly produced in a suspension cell in a large scale; through removal of virus cell membrane protein genes, the virus cell membrane protein genes cannot be continuously replicated in vivo, so that the safety of the virus cell membrane protein genes is ensured, the tumor immunosuppression condition is improved, and an organism can be stimulated to generate a neutralizing antibody for resisting new coronavirus while tumor cells are killed.

Disclosed herein is a new method referred to as Conformational Shifting by Distance and Volume Analysis (CS-DVA) which can be employed to change the dynamics of multi-state glycoproteins for altered immune responses. Also disclosed are stabilized spike antigens and methods of use thereof for SARS-COV-2 vaccines.

The present disclosure relates to compositions and methods for vaccinating a subject against a variety of SARS-CoV-2 variants and other respiratory viruses, the compositions and methods involve preparing and delivering extracellular vesicles expressing on its surface an engineered spike protein, an engineered nucleocapsid protein, an engineered hemagglutinin protein, and / or an engineered respiratory syncytial virus pre-fusion or fusion (RSV F) protein. The invention also relates to compositions and methods for designing, preparing, making, formulating and / or using spike display, nucleocapsid display, hemagglutinin display and / or RSV F display vesicle vaccines, the spike display, nucleocapsid display, hemagglutinin display, and / or RSV F display vesicle vaccines are designed to elicit potent humoral and cellular immune responses against a variety of respiratory viruses and variants.

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

The present invention relates to treatment of COVID-19 and methods thereof. A vaccine composition for inducing immunity against coronavirus in a subject comprises a recombinant nucleic acid encoding an N-ETSD, which is a modified nucleocapsid protein comprising an endosomal targeting sequence, and / or a recombinant nucleic acid encoding an S-fusion, which is a modified spike protein with improved surface expression. The vaccines can be formulated as recombinant nucleic acids, recombinant yeasts, and / or recombinant viruses, such as adenoviruses, and can be administered via injection and / or mucosal delivery.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The present invention pertains to protein oligomers for active immunization. Specifically, the invention relates to protein oligomers comprising at least a first monomer and a second 5 monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first RBD, an immunoglobulin Fc (Ig Fc), and at least one second RBD, wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or a fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13. The invention further relates to a vaccine comprising said protein oligomer, preferably for use in active immunization and / or booster vaccination in a subject.

An immunotherapeutic protein and methods of use and production thereof are disclosed, wherein the immunotherapeutic protein comprises, for example, a cell surface receptor polypeptide which is a cellular entry receptor for the entry of a virus into a host cell, which is linked to a polypeptide comprising an Fc region component. When the cell surface receptor polypeptide is an angiotensin converting enzyme 2 (ACE2) polypeptide or a fragment thereof, the immunotherapeutic protein is capable of binding to a coronavirus spike protein (S protein) and may be useful as an antiviral agent for the prevention or treatment of a coronavirus infection. The Fc region component may comprise an amino acid substitution at the position corresponding to H429 of the amino acid sequence of the human IgG1 heavy chain polypeptide which may enable the production of soluble oligomeric forms or the assembly of oligomeric forms from soluble monomeric forms upon binding to an S protein of a coronavirus (i.e. as present on a virion or the surface of virus-infected cells).

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and / or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-COV-2, and methods and uses thereof in the prevention, treatment and / or diagnosis of coronavirus infections, and diseases and / or complications associated with coronavirus infections, including COVID-19.

Methods, systems, and devices are provided for predicting the robustness of an antibody response of a subject to the SARS-COV-2 spike protein receptor binding domain based on measurement of physiological metrics following vaccination. In particular, one or more physiological metrics of the subject selected from dermal temperature deviation, heart rate, respiratory rate, heart rate variability, and deep sleep duration are measured with a wearable device before and after vaccinating the subject, wherein increases in dermal temperature deviation, heart rate, and respiratory rate, and decreases in heart rate variability on the first night after administration of the vaccine to the subject are correlated with greater antibody responses to the SARS-COV-2 spike protein.

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

The present invention relates to a binding molecule that binds to SARS-coronavirus-2 (SARS-CoV-2). More particularly, the binding molecule of the present invention has strong ability to bind to a spike protein (S protein) on the surface of SARS-coronavirus-2 and high neutralizing activity against SARS-coronavirus-2 and is thus very useful in the diagnosis, prevention or treatment of SARS-coronavirus infection (COVID-19).

The present disclosure provides vaccines and compositions of spike proteins (S proteins) based on different Omemitron variants of SARS-CoV-2, and in particular relates to recombinant SARS-CoV-2S proteins, and mRNA and DNA encoding the same. The present disclosure also relates to recombinant plasmids comprising a DNA sequence encoding a recombinant S protein. The disclosure further relates to compositions, mRNA-vector particles, e.g., lipid nanoparticles (LNP), and compositions, e.g., vaccine compositions, comprising the aforementioned recombinant S protein and / or mRNA.

The present invention pertains to pharmaceutical compositions comprising protein oligomers for passive immunization and therapy. Specifically, the present invention relates to a pharmaceutical composition comprising a protein oligomer comprising at least a first and a second monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first receptor binding domain (RBD), an immunoglobulin Fc (Ig Fc), and at least one second receptor binding domain (RBD), wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13.